UroGen Pharma Ltd. (NASDAQ:URGN – Get Free Report) insider Mark Schoenberg sold 859 shares of the business’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $13.08, for a total value of $11,235.72. Following the completion of the transaction, the insider now directly owns 145,091 shares of the company’s stock, valued at $1,897,790.28. The transaction was disclosed in a legal filing with the SEC, which is available at this link.
UroGen Pharma Stock Performance
URGN opened at $13.12 on Friday. The firm’s 50-day moving average price is $15.15 and its 200-day moving average price is $14.96. The company has a market cap of $307.66 million, a P/E ratio of -3.86 and a beta of 1.11. The company has a quick ratio of 7.93, a current ratio of 8.15 and a debt-to-equity ratio of 3.23. UroGen Pharma Ltd. has a 52-week low of $10.60 and a 52-week high of $20.70.
UroGen Pharma (NASDAQ:URGN – Get Free Report) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($0.91) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.09). The business had revenue of $21.85 million for the quarter, compared to analyst estimates of $23.69 million. As a group, equities analysts anticipate that UroGen Pharma Ltd. will post -3.49 EPS for the current fiscal year.
Institutional Inflows and Outflows
Analyst Upgrades and Downgrades
A number of equities analysts have commented on the stock. Guggenheim assumed coverage on shares of UroGen Pharma in a report on Thursday, August 22nd. They issued a “buy” rating and a $40.00 target price for the company. HC Wainwright reissued a “buy” rating and set a $60.00 target price on shares of UroGen Pharma in a research report on Wednesday, August 14th. Oppenheimer lifted their price target on shares of UroGen Pharma from $32.00 to $40.00 and gave the stock an “outperform” rating in a report on Friday, June 14th. Finally, LADENBURG THALM/SH SH increased their price objective on UroGen Pharma from $48.00 to $53.50 and gave the company a “buy” rating in a report on Friday, June 14th.
Check Out Our Latest Stock Analysis on URGN
UroGen Pharma Company Profile
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.
Read More
- Five stocks we like better than UroGen Pharma
- Stock Splits, Do They Really Impact Investors?
- Symbotic’s Double-Bagger Potential as It Hits a Key Inflection
- What is the Dogs of the Dow Strategy? Overview and Examples
- High Dividend Yields Make These 2 Shipping Stocks Stand Out
- ESG Stocks, What Investors Should Know
- Can Celsius Stock Rebound? Analysts See 74% Upside Potential
Receive News & Ratings for UroGen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UroGen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.